Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets
作者： Christopher J Barnes , Rakesh Kumar
关键词:
摘要: Activating mutations, gene amplification and overexpression of human epidermal growth factor receptor (erbB or HER) family kinases have been implicated as integral contributors to a variety cancers. However, there is increasing evidence that the HER receptors propagate not only signals initiated by their own ligands but also those multiple other signaling pathways. Attenuation developing strategy for management malignancies subject number ongoing clinical trials. The purpose this review provide timely update recent reports in rapidly evolving area biology emerging role these malignant transformation targets cancer therapy.
springer.com
sci-hub.se 参考文章(46)
M. C. Hung, G. N. Hortobagyi, N. T. Ueno, Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. Advances in Experimental Medicine and Biology. ,vol. 465, pp. 171- 180 ,(2002) , 10.1007/0-306-46817-4_16
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
Kotha Subbaramaiah, Kotha Subbaramaiah, Howard T. Thaler, Baoheng Du, Louise R. Howe, Anthony M. C. Brown, Jaime L. Masferrer, Clifford Hudis, William J. Muller, Andrew J. Dannenberg, Jay Patel, Aparna Deora, Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Research. ,vol. 62, pp. 5405- 5407 ,(2002)
Hyun-Soo Cho, Daniel J Leahy, Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether Science. ,vol. 297, pp. 1330- 1333 ,(2002) , 10.1126/SCIENCE.1074611
Steve Ebbs, Mitch Dowsett, Irene Boeddinghaus, Catherine Harper-Wynne, Ian Smith, Mike Dixon, Gerald Gui, Janine Salter, Margaret Hills, Nigel Sacks, HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer Cancer Research. ,vol. 61, pp. 8452- 8458 ,(2001)
Christopher C. Benz, Fan Xu, Chloe Marden, Liana Kirk, Gary K. Scott, Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Molecular Cancer Therapeutics. ,vol. 1, pp. 385- 392 ,(2002)
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
Thomas P.J. Garrett, Neil M. McKern, Meizhen Lou, Thomas C. Elleman, Timothy E. Adams, George O. Lovrecz, Hong-Jian Zhu, Francesca Walker, Morry J. Frenkel, Peter A. Hoyne, Robert N. Jorissen, Edouard C. Nice, Antony W. Burgess, Colin W. Ward, Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α Cell. ,vol. 110, pp. 763- 773 ,(2002) , 10.1016/S0092-8674(02)00940-6
M PEGRAM, D REESE, Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Seminars in Oncology. ,vol. 29, pp. 29- 37 ,(2002) , 10.1016/S0093-7754(02)70124-3
Rozita Bagheri-Yarmand, Ratna K. Vadlamudi, Rui-An Wang, John Mendelsohn, Rakesh Kumar, Vascular Endothelial Growth Factor Up-regulation via p21-activated Kinase-1 Signaling Regulates Heregulin-β1-mediated Angiogenesis Journal of Biological Chemistry. ,vol. 275, pp. 39451- 39457 ,(2000) , 10.1074/JBC.M006150200